.jetcityimage/iStock Editorial by means of Getty Images Morgan Stanley has selected Eli Lilly (NYSE: LLY) as its own leading biopharma pick for 2025 as well as measured another 9 labels in the room as overweight. The financial investment bank pointed out in a details that it continues to feel “diabesity is actually set to come to be.